Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$47.53 USD

47.53
2,174,247

-0.91 (-1.88%)

Updated Jun 13, 2024 04:00 PM ET

After-Market: $47.54 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 249)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat

Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.

    Bayer (BAYRY) Q2 Earnings Beat, Sales Miss, Cuts Guidance

    Bayer AG (BAYRY) topped earnings but missed sales expectations in Q2. The company also lowered its guidance for full-year 2017.

      Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View

      Bristol-Myers (BMY) reports encouraging second-quarter results, beating both earnings and sales estimates.

        Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View

        Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.

          Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat

          Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.

            Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed

            Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.

              Merck's Biosimilar Insulin Gets Tentative FDA Approval

              Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

                Arpita Dutt headshot

                Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

                Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

                  Sarepta & BioMarin Settle Patent Litigation on Exon Skipping

                  Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.

                    Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt

                    Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.

                      Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?

                      Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                        Perrigo Company Gets FDA Approval for Generic Topical Gel

                        Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.

                          Sheraz Mian headshot

                          Early Read on the Q2 Earnings Season

                          I am reasonably confident that we are on our way for another reassuring earnings read.

                            AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

                            AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

                              Swarup Gupta headshot

                              Foreign Stock Roundup: Infosys Beats, Taiwan Semiconductor Misses

                              Dovish comments from Yellen helped global stocks post gains.

                                Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit

                                Emergent BioSolutions Inc. (EBS) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY) in an all-cash deal of up to $125 million.

                                  Pfizer Xeljanz Label Expansion Application Accepted by FDA

                                  Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.

                                    Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.

                                      Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD

                                      Mallinckrodt plc (MNK) announced that the FDA has granted orphan drug designation to its pipeline candidate - MNK-1411, which is being evaluated for the treatment of Duchenne muscular dystrophy (DMD).

                                        Lilly Settles Patent Litigation on Cialis with Generic Firms

                                        Eli Lilly & Company (LLY) announced that it has entered into an agreement with generic companies to settle a patent relating to its erectile dysfunction drug Cialis (tadalafil).

                                          Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform

                                          We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.

                                            Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth

                                            On Jul 11, Alnylam Pharmaceuticals Inc. (ALNY) was upgraded to a Zacks Rank #2 (Buy).

                                              Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data

                                              Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.

                                                Sanofi to Buy Vaccine Biotech Protein Sciences for $650M

                                                Sanofi (SNY), on Monday, announced plans to buy a Meriden, CT-based private vaccine biotech, Protein Sciences for an upfront payment of $650 million.

                                                  Are Medicines Company's Key Drugs Set for Growth in 2017?

                                                  On Jul 7, 2017, we issued an updated report on The Medicines Company (MDCO).